GENERAL INFORMATION | |||
---|---|---|---|
Company name: | Brilitas Pharmaceuticals EU OÜ | ||
Address: | Pärnu mnt 139c , Harju maakond, Kesklinna linnaosa, 11317 Tallinn, Estonia | ||
Web: | Brilitas.com | ||
Company creation date: | 2022 | ||
Employees: | 11 | ||
Field of activity: | Human/Veterinary | ||
Record last updated on: | 08/03/2023 | ||
CONTACT DETAILS | |||
Contact name: | Dang Tran Quang | ||
Tel: | +84 888 332 899 | ||
Fax: | |||
Email: | info-ee@brilitas.com | ||
COMPANY SECTOR | |||
(Bio)Pharmaceutical: | |||
Early manufacturing/Research&Discovery stage: | |||
Development stage: | |||
Commercialisation/Marketing stage (EU/Non-EU): | |||
Medical Device and Technology: | |||
Development stage: | |||
Commercialisation/Marketing stage (EU/Non-EU): | |||
PRODUCT INFORMATION | |||
Medicinal Products | |||
Vaccines: | |||
Therapeutic medicines: | |||
Diagnostic and imaging products: | |||
Combined medicinal products and devices: | |||
Product Development Stages | Number of Products |
||
Research/Discovery: | 2 |
||
Pharmaceutical development: | 5 |
||
Preclinical: | 2 |
||
Clinical exploratory: | 1 |
||
Clinical confirmatory: | 1 |
||
(Pre)registration (EU/Non-EU): | |||
Marketing (EU/Non-EU): | |||
SUBSTANCES | |||
Chemicals | |||
Single entities | |||
Combinations of single entities | |||
Peptides (chemically synthesised) | |||
Biologically derived proteins and peptides | |||
Monoclonal antibodies | |||
Recombinant proteins | |||
Extracted proteins | |||
Nucleic acids (chemically synthesised) | |||
RNA | |||
DNA | |||
Polymer (natural and synthetic - excluding peptides, proteins and nucleic acids) | |||
Homopolymers | |||
Copolymers | |||
Advanced therapy medicinal products (in accordance with EC 1394/2007) | |||
Somatic cell therapy products | |||
Tissue engineered products | |||
Gene therapy products | |||
Radionuclides | |||
Allergens | |||
Polyclonal immunoglobulins | |||
Herbal derived complex substances | |||
Animal derived complex substances | |||
SPECIFIC PRODUCT CATEGORIES | |||
Biodefense | |||
Biosimilars | |||
Excipients | |||
Foods (Functional foods, nutraceuticals) | |||
Generics | |||
Genetically modified organisms (GMOs) | |||
Homeopathics | |||
Maximum Residue Limits (Veterinary products) | |||
Medical devices | |||
Medicines for tropical diseases | |||
MUMS (Minor Use/Minor Species) /Limited Market (Veterinary products) | |||
Nanotechnology (including microparticles, liposomes, microbeads) | |||
New formulations/delivery methods | |||
Orphan medicines (in accordance with Orphan Drug Regulation EC/141/2000) | |||
OTC (Over the counter)/Non prescription/self medication | |||
Paediatric medicines | |||
Stem cells | |||
Theranostics (personalised/targeted products, biomarkers,(pharmaco)genomics) | |||
Transgenic technology | THERAPEUTIC AREA (assigned or expected ATC codes) | ||
A Alimentary tract and metabolism | |||
B Blood and blood forming organs | |||
C Cardiovascular system | |||
D Dermatologicals | |||
G Genito-urinary system and sex hormones | |||
H Systemic hormonal preparations, excluding sex hormones | |||
J General anti-infectives for systemic use | |||
L Anti-neoplastic and immunomodulating agents | |||
M Musculo-skeletal system | |||
N Nervous system | |||
P Anti-parasitic products, Insecticides, Repellents | |||
R Respiratory system | |||
S Sensory organs | |||
V Various | |||
Back to list |